BioMarin Pharmaceutical (BMRN) Stock Forecast, Price & News

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BMRN shares.
View BMRN analyst ratings or view top-rated stocks.

19 analysts have issued 12-month price objectives for BioMarin Pharmaceutical's shares. Their BMRN share price forecasts range from $74.00 to $200.00. On average, they expect the company's share price to reach $118.65 in the next twelve months. This suggests a possible upside of 36.0% from the stock's current price.
View analysts price targets for BMRN or view top-rated stocks among Wall Street analysts.

BioMarin Pharmaceutical's stock was trading at $103.49 on January 1st, 2023. Since then, BMRN shares have decreased by 15.7% and is now trading at $87.22.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our BMRN earnings forecast.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) posted its quarterly earnings results on Tuesday, October, 26th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.05. The biotechnology company had revenue of $408.74 million for the quarter, compared to analysts' expectations of $435.29 million. BioMarin Pharmaceutical had a net margin of 3.30% and a trailing twelve-month return on equity of 4.02%. The firm's revenue was down 14.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.29 EPS.

ETFs with the largest weight of BioMarin Pharmaceutical (NASDAQ:BMRN) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), Global X Genomics & Biotechnology ETF (GNOM), VanEck Biotech ETF (BBH), Goldman Sachs Future Health Care Equity ETF (GDOC), First Trust NYSE Arca Biotechnology Index Fund (FBT), VictoryShares Nasdaq Next 50 ETF (QQQN), Touchstone US Large Cap Focused ETF (LCF) and Invesco Nasdaq Biotechnology ETF (IBBQ).

BioMarin Pharmaceutical issued an update on its FY 2023 earnings guidance on Thursday, April, 27th. The company provided EPS guidance of $1.80-$2.05 for the period, compared to the consensus estimate of $0.95. The company issued revenue guidance of $2.38 billion-$2.50 billion, compared to the consensus revenue estimate of $2.46 billion.

228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX).

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

BioMarin Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional shareholders include Dodge & Cox (7.63%), Ameriprise Financial Inc. (2.63%), Avoro Capital Advisors LLC (2.10%), Baker BROS. Advisors LP (2.03%), Geode Capital Management LLC (1.42%) and Pictet Asset Management SA (1.09%). Insiders that own company stock include Brian Mueller, Charles Greg Guyer, David E I Pyott, Dennis Slamon, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Mark J Alles, Michael G Grey, Richard A Meier, V Bryan Lawlis and Willard H Dere.
View institutional ownership trends.

Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BMRN stock can currently be purchased for approximately $87.22.

BioMarin Pharmaceutical (NASDAQ:BMRN) has a market capitalization of $16.37 billion and generates $2.17 billion in revenue each year. The biotechnology company earns $141.56 million in net income (profit) each year or $0.38 on an earnings per share basis.

The company employs 3,082 workers across the globe.

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The official website for the company is www.bmrn.com. The biotechnology company can be reached via phone at (415) 506-6700, via email at ir@bmrn.com, or via fax at 415-382-7889.